Clik here to view.
Novocure Announces Data Presentations at the IASLC 18th World Conference on...
ST. HELIER, Jersey Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer,...
View ArticleClik here to view.
Eternity Healthcare Inc. Announces Plans to Build a 50,000 Square Foot Stem...
NEW YORK Eternity Healthcare (“Eternity” or the “Company”) (OTC: ETAH) has announced its intention to build a cell storage, transformation and application facility in Tongren, Guizhou Province,...
View ArticleClik here to view.
Avita Announces New Chief Financial Officer; Existing CFO Moves to Chief...
VALENCIA, Calif. & PERTH, Australia & LONDON Avita Medical (ASX:AVH) (OTCQX:AVMXY), a regenerative medicine company with a technology platform positioned to address opportunities and unmet...
View ArticleClik here to view.
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a...
OSAKA, Japan & LEUVEN, Belgium Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for...
View ArticleClik here to view.
Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho...
NEW YORK Eternity Healthcare (“Eternity” or the “Company”) (OTC: ETAH) today announced that it has entered into a share exchange agreement (the “Exchange Agreement”) dated December 13, 2017, with...
View ArticleClik here to view.
SanBio Primary Researcher Receives 2017 Smithsonian American Ingenuity Award
MOUNTAIN VIEW, Calif. SanBio, Inc., a leader in regenerative cell therapies for neurological disorders, joins the Smithsonian Institution in recognizing Stanford University’s Dr. Gary Steinberg,...
View ArticleClik here to view.
Korean Urologist Dr. Dori Kim Got Praises for SVF Applied ‘SST phalloplasty’
SEOUL, South Korea Stantop Urology Clinic, located in Gangman, Seoul, announced that allogenic derma applied SST phalloplasty developed by its representative doctor Dori Kim is getting praises from...
View ArticleClik here to view.
Positive Pre-Clinical Results Using CelGro® in Anterior Cruciate Ligament...
PERTH, Australia Regenerative medicine company Orthocell Limited (ASX:OCC) (“Orthocell” or the “Company”) is pleased to announce positive pre-clinical results using CelGro® collagen rope for...
View ArticleClik here to view.
PharmAbcine与默沙东合作开展TTAC-0001与KEYTRUDA®（派姆单抗）联合治疗复发性胶质母细胞瘤和乳腺癌的临床评估
韩国大田 (美国商业资讯) — PharmAbcine Inc.是一家临床阶段生物技术公司，开发用于多种癌症适应证的新型抗体治疗药物，该公司宣布其分公司与默沙东（美国肯纳尔沃思默克公司的商标名）已签署合作协议，评估PharmAbcine的抗VEGFR2...
View ArticleClik here to view.
ファーマブシン、再発膠芽腫と乳がんでキイトルーダ（ペムブロリズマブ）と併用したTTAC-0001の臨床評価に傾注するためMSDとの協業契約を締結
韓国・テジョン （ビジネスワイヤ） — 複数のがん適応症に対する新しい抗体医薬品の開発に当たっている臨床開発段階のバイオテクノロジー企業ファーマブシンは、子会社を通じてMSD（米ニュージャージー州ケニルワースのMerck & Co., Inc.の商号）と協業契約を結び、再発多形性膠芽腫（rGBM）患者と転移性トリプルネガティブ乳がん（TNBC）患者でファーマブシンの抗VEGFR2...
View ArticleClik here to view.
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to...
View ArticleClik here to view.
サンバイオ：再生細胞薬「SB623」の開発進捗総括の更新について
東京 （ビジネスワイヤ） — 平成30年３月13日付リリース『再生細胞薬「SB623」の開発進捗総括の更新について』に記載した「SB623」の開発の進捗に動きがあり、これに伴い一部の内容を更新しました。更新箇所は下線の部分であります。 記...
View ArticleClik here to view.
SanBio: Update on Development Progress of Regenerative Cell Medicine SB623
TOKYO The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio Inc.) (TOKYO:4592) has updated part of its March 13, 2018 release “Update on Development Progress of Regenerative Cell Medicine SB623”....
View ArticleClik here to view.
PharmAbcine宣布，FDA向用于多形性胶质母细胞瘤的TTAC-0001签发孤儿药认证
韩国大田 (美国商业资讯) — PharmAbcine Inc.是一家临床阶段生物技术公司，开发用于多种癌症适应证的新型抗体治疗药物，该公司今天宣布，美国食品药品管理局(FDA)已向该公司用于“治疗多形性胶质母细胞瘤”的领先临床化合物TTAC-0001签发了孤儿药认证。 PharmAbcine, Inc.总裁兼首席执行官Jin-San...
View ArticleClik here to view.
ファーマブシン、FDAが多形性膠芽腫治療薬TTAC-0001を希少疾病用医薬品に指定したと発表
韓国・テジョン （ビジネスワイヤ） — 複数のがん適応症に対する新規抗体医薬品の開発に当たっている臨床開発段階のバイオテクノロジー企業ファーマブシンは、米国食品医薬品局（FDA）が「多形性膠芽腫治療」のための当社の有力臨床化合物TTAC-0001を希少疾病用医薬品に指定したと発表しました。 ファーマブシンの社長兼最高経営責任者（CEO）であるJin-San...
View ArticleClik here to view.
RECELL® Study in Facial Burns Shows Excellent Cosmetic Outcomes
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today results from a clinical study highlighting the potential benefits of the RECELL® Autologous Cell...
View ArticleClik here to view.
RECELL® Pivotal Trial in Third-Degree Burns Meets Co-Primary Endpoints and...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that its pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree)...
View ArticleClik here to view.
Promethera Biosciences Establishes Branch Office in Tokyo
MONT-SAINT-GUIBERT, Belgium & TOKYO Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the foundation of a new branch office in Tokyo,...
View ArticleClik here to view.
AVITA Medical Announces Presentation at ISPOR Meeting Validating Acute Burn...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from a study validating the predicted outcomes and costs from an acute burns health...
View ArticleClik here to view.
Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and...
TOKYO The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that Cell Therapy for Chronic Stroke,...
View Article